Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

Annals of Oncology

Volumn 12, Issue 9, 2001, Pages 1247-1254

  O'Shaughnessy, J A ^a   Blum, J ^a   Moiseyenko, V ^b   Jones, S E ^a   Miles, D ^c   Bell, D ^d   Rosso, R ^e   Mauriac, L ^f   Osterwalder, B ^g   Burger, H U ^g   Laws, S ^h  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^c GUY S HOSPITAL   (United Kingdom)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e UNIVERSITY OF GENOA   (Italy)

^f INSTITUT BERGONIÉ   (France)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h IQVIA   (United States)

Author keywords

Breast cancer; Capecitabine; CMF; First line; Oral fluoropyrimidine

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HAND FOOT AND MOUTH DISEASE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; METASTASIS; MULTICENTER STUDY; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME;

EID: 0034778024     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012281104865     Document Type: Article

References (21)

1. Breast cancer: Epidemiology, risk factors, screening
2. Cancer Statistics 1996
3. Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990
4. Current management of metastatic breast cancer
5. Patient preferences for oral vs. intravenous palliative chemotherapy
6. A study of quality of life in cancer patients receiving palliative chemotherapy
7. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue
8. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
9. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients
10. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
11. A multicenter phase II trial of Xeloda™ (capecitabine) in taxane-refractory metastatic breast cancer
12. A randomized phase II study of Xeloda™ (capecitabine) vs. paclitaxel in breast cancer patients failing previous anthracycline therapy
13. Treatment of breast cancer
14. Optimising chemotherapy for patients with advanced breast cancer
15. Mitoxantrone, 5-fluorouracil and high dose leucovorin (NFL) in the treatment of metastatic breast cancer: Randomized comparison to cyclophosphamide, methotrexate and 5-fluorouracil (infusional CMF) and adding paclitaxel
16. 'Classical' CMF vs. a three-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer
17. Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer
18. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine)
19. Cytotoxic and hormonal treatment for metastatic breast cancer: A systemic review of published randomized trials involving 31.510 women
20. Oral 5-FU analogues in the treatment of breast cancer